

7. Trucco G, Fritsch R, Giorda R, Trucco M (1989) Rapid detection of IDDM susceptibility with HLA-DQ  $\beta$ -alleles as markers. *Diabetes* 38: 1617–1622
8. Kawaguchi Y, Ikegami H, Fukuda M, Fujioka Y, Shima K, Ogiwara T (1993) Polymorphism of HSP70 gene is not associated with type 1 (insulin-dependent) diabetes mellitus in Japanese. *Diabetes Res Clin Pract* 21: 103–107
9. Demaine AG, Hibberd ML, Mangles D, Millward BA (1995) A new marker in the HLA class I region is associated with the age at onset of IDDM. *Diabetologia* 38: 623–628
10. Faustman D, Li X, Lin HY et al. (1991) Linkage of faulty major histocompatibility complex class I to autoimmune diabetes. *Science* 254: 1756–1761
11. Ikegami H, Kawaguchi Y, Ueda H et al. (1993) MHC-linked diabetogenic gene of the NOD mouse: molecular mapping of the 3' boundary of the diabetogenic region. *Biochem Biophys Res Commun* 192: 677–682
12. Miyazaki T, Matsuda Y, Toyonaga T, Miyazaki J-I, Yazaki Y, Yamamura K-I (1992) Prevention of autoimmune insulinitis in nonobese diabetic mice by expression of major histocompatibility complex class I Ld molecules. *Proc Natl Acad Sci USA* 89: 9519–9523

## Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene

Dear Sir,

We read with great interest the recent paper published in *Diabetologia* by Tarnow et al. [1].

A considerable part of the data in this paper is also contained in a paper recently published in *Diabetes* [2] by the same group. These areas include the 'Subjects and methods' section which is very similar between the two papers. The data in Table 1 of both papers is more than 75% identical.

The beginning of the 'Results' section contains identical data and the text is the same. Both papers present the results of angiotensin converting enzyme (ACE) genotyping in patients with nephropathy compared to those with normoalbuminuria. The *Diabetes* paper also presents these data in a Table. Both papers have presented the same plasma ACE levels with respect to ACE genotypes as well as nephropathy and normoalbuminuria. The *Diabetes* paper has also presented the data in a Table.

It is of particular interest that both papers were received on the same day (10 October 1994) in the editorial offices of *Diabetologia* and *Diabetes*. The *Diabetologia* paper makes only a brief reference to the *Diabetes* paper [ref. 36]. The revised form of the *Diabetologia* paper was received on 20 December 1994 whilst the revised *Diabetes* paper was received on 19 January 1995. With respect to the *Diabetes* paper the authors must have known that the *Diabetologia* paper was likely to be accepted yet no mention of its existence or the data regarding coronary heart disease (CHD) has been made. Consequently, the discussion in the *Diabetes* paper has been written with no

mention of the role of CHD in nephropathy despite the authors' having a paper which looks at CHD in exactly the same group of patients. This is very misleading for the reader and the discussion in the *Diabetes* paper has been written without disclosing the full facts.

Finally, the 'Statement to be signed by all authors' for submission of manuscripts to *Diabetologia* states 'We confirm that neither the manuscript submitted nor any part of it has been published or is being considered for publication elsewhere . . .' clearly this is not the case. Likewise, *Diabetes* also requires a statement where 'authors must state in their transmittal letter that the material has not been published or submitted simultaneously to another journal'.

We believe that it is very poor scientific practice for a group to attempt to publish data twice.

Yours sincerely,

A. Demaine, M. Hibberd, A. Millward

## References

1. Tarnow L, Cambien F, Rossing P et al. (1995) Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. *Diabetologia* 38: 798–803
2. Tarnow L, Cambien F, Rossing P et al. (1995) Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. *Diabetes* 44: 489–494

## Response from the authors

Dear Sir,

Drs. A. Demaine, M. Hibberd, and A. Millward believe 'that it is very poor scientific practice for a group to attempt to publish data twice'. We completely agree and consequently we have never done so and do not intend to in the future. Actually, *Diabetologia* received a full copy of the paper submitted to *Diabetes* before acceptance. However, we are puzzled and astonished over the accusation since we are planning to publish many more papers (an additional one has already been accepted by *Diabetes* and another two have been submitted to *Diabetes*/*Diabetologia*) based on our large case/control study consisting of 198 insulin-dependent diabetic (IDDM) patients with diabetic nephropathy and a matched group of 190 IDDM patients with normoalbuminuria. The two groups have been carefully evaluated in relation to demographic data, microangiopathy, macroangiopathy, autonomic neuropathy, cardiovascular risk factors, endothelial dysfunction etc. DNA was isolated from all patients. The reason for conducting such a large case/control study was to answer questions within the following topics:

1. Importance of genetic abnormalities in relation to initiation and progression of diabetic nephropathy and diabetic retinopathy.

2. Importance of genetic abnormalities in relation to initiation and progression of diabetic nephropathy and diabetic retinopathy.

2. To unravel genetic abnormalities in relation to development of coronary heart disease.

3. Evaluation of "new" cardiovascular risk factors.

4. To follow the patient groups prospectively in order to evaluate the importance of genetic and non-genetic factors for the development and progression of diabetic micro- and macroangiopathy.

Thus, it is evident that the material will be the same in the past and in the publications to come. However, different measurements will be applied to evaluate the different topics referred to above, exactly as was carried out in the publications mentioned in *Diabetologia* and *Diabetes*. In the *Diabetes* paper we were studying a role of the insertion/deletion polymorphism in the angiotensin converting enzyme in relation to diabetic nephropathy and diabetic retinopathy. The paper published in *Diabetologia* was dealing with the importance of the same polymorphism but in relation to the development of cor-

onary heart disease, of course taking into account numerous well-known cardiovascular risk factors. Finally, we would like to stress that large well-characterized patient materials can be used for the answering of many different questions as attempted in our study. Without comparison, we would like to mention that in addition to the original publication of the Diabetes Control and Complications Trial (DCCT) data in the *New England Journal of Medicine* an estimated 30–40 additional publications from that study will be available, as well as the numerous important publications in the *British Medical Journal* by D. J. P. Barker et al. based on the Hertfordshire material.

Yours sincerely,

L. Tarnow  
H.-H. Parving

## Errata

### Diabetologia

Volume 38 Number 9 pp 1014–1024

C. K. Leow, D. W. R. Gray, P. J. Morris

#### The long-term metabolic function of intraportal and renal subcapsular islet isografts and the effect of glomerular basement membrane thickness in rats

Due to an error part of the legend to Figure 1 was transposed, the correct legend is printed here

**Fig. 1.** Non-fasting plasma glucose of rats given 1000 or 3000 islets IP or SC and followed for either 6 months or 12 months, compared to normal and diabetic controls. ( $\Delta$ --- $\Delta$ ) 1000 islets IP followed 6 months, ( $\bullet$ --- $\bullet$ ) 1000 islets SC followed 6 months, ( $\circ$ --- $\circ$ ) 3000 islets IP followed 6 months, ( $\blacktriangle$ --- $\blacktriangle$ ) 3000 islets SC followed 6 months, ( $\blacksquare$ --- $\blacksquare$ ) 1000 islets IP followed 12 months, ( $\bullet$ --- $\bullet$ ) 1000 islets SC followed 12 months, ( $\blacktriangle$ --- $\blacktriangle$ ) 3000 islets IP followed 12 months, ( $\Delta$ --- $\Delta$ ) 3000 islets SC followed 12 months, ( $\square$ --- $\square$ ) normal controls from 6 month follow up groups, ( $\blacksquare$ --- $\blacksquare$ ) normal controls from 12 month study groups, ( $\square$ --- $\square$ ) diabetic controls from 6 month study groups, ( $\blacktriangle$ --- $\blacktriangle$ ) diabetic controls from 12 month study groups. Error bars indicate SEM

### Diabetologia

Volume 38 Number 10 pp 1249–1250

#### The glycogen synthase gene in NIDDM and hypertension

Y. Hamada, H. Ikegami, Y. Fujioka, E. Yamato, K. Takekawa, T. Fujisawa, Y. Nakagawa, H. Ueda, J. Fu, G.-Q. Shen, T. Miki, T. Ogihara

Due to an unfortunate error Dr. Miki's name was incorrectly printed in the above-mentioned letter to the editor